Journal
REVIEWS ON RECENT CLINICAL TRIALS
Volume 14, Issue 1, Pages 72-76Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1574887113666180726103648
Keywords
Aliskiren; IgA GMN; proteinuria; conventional therapies; case report; Chronic Kidney Disease (CKD)
Categories
Ask authors/readers for more resources
Introduction: The early suspension of Altitude trial in recent years has induced most nephrologists and cardiologists to abandon Aliskiren use. Consequently, the potential usefulness of the direct renin inhibition in IgA glomerulonephritis remained an under-investigated therapeutic option. Case Report: We report the case of a 53 years old IgA GMN patient unresponsive to all conventional anti-angiotensin-2 agents, steroids and immunosuppressants, in which the administration of Aliskiren permitted to achieve and maintain a complete proteinuria remission in the absence of any adverse event. Conclusion: Aliskiren might represent a valid and safe therapeutic option in IgA GMN, although further investigations would be needed to confirm this conclusion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available